Elicio Therapeutics, Inc. (ELTX) has a negative trailing P/E of -3.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -25.79%.
Criteria proven by this page:
Overall SharesGrow Score: 38/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2012 | 0.1 | 0.00 | 0.02 | 0.00 | - |
| 2013 | 0.1 | 0.00 | 0.02 | 0.01 | - |
| 2018 | -0.9 | 0.00 | 0.92 | 4.31 | - |
| 2019 | -1.2 | 0.02 | -2.58 | 32.28 | - |
| 2020 | -0.6 | -0.02 | -0.53 | 16.67 | - |
| 2021 | -0.7 | 0.00 | 0.23 | 0.67 | - |
| 2022 | -0.6 | 0.01 | 2.05 | 0.00 | - |
| 2023 | -1.2 | 0.05 | 3.71 | 0.00 | - |
| 2024 | -1.2 | 0.03 | -5.50 | 0.00 | - |
| 2025 | -3.1 | 0.08 | 74.50 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2012 | $50.21 | $7.3M | $307.3K | 4.2% |
| 2013 | $103.31 | $6.58M | $632.24K | 9.6% |
| 2018 | $-6.79 | $4.03M | $-20.03M | -497% |
| 2019 | $-1.50 | $1.49M | $-12.26M | -824.5% |
| 2020 | $-1.93 | $2.88M | $-15.71M | -545.6% |
| 2021 | $-8.25 | $28.31M | $-26.4M | -93.2% |
| 2022 | $-9.10 | $0.00 | $-28.21M | - |
| 2023 | $-6.96 | $0.00 | $-35.2M | - |
| 2024 | $-4.25 | $0.00 | $-51.9M | - |
| 2025 | $-2.58 | $0.00 | $-39.57M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.50 | $-1.50 – $-1.50 | $20M | $20M – $20M | 1 |
| 2027 | $-1.40 | $-1.40 – $-1.40 | $0.00 | $0.00 – $0.00 | 1 |
| 2028 | $-1.45 | $-1.45 – $-1.45 | $0.00 | $0.00 – $0.00 | 1 |
